Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Reperfusion injury is a significant complication following myocardial infarction.
• Sodium thiosulfate (STS) is a potent antioxidant and hydrogen sulfide donor with potential cardioprotective properties.

Purpose of the Study:

• To investigate the efficacy of sodium thiosulfate (STS) in reducing myocardial reperfusion injury.
• To evaluate the impact of STS on infarct size and clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients.

Main Methods:

• A proof-of-principle, randomized trial involving 373 STEMI patients.
• Patients received either intravenous STS (12.5 g) or placebo at hospital arrival and 6 hours later.
• Infarct size was assessed by cardiac magnetic resonance imaging at 4 months.

Main Results:

• The primary outcome, infarct size, showed no significant difference between the STS and placebo groups.
• Secondary clinical outcomes were also comparable between the treatment arms.
• The study did not demonstrate a clinical benefit of STS in this patient population.

Conclusions:

• Sodium thiosulfate (STS) administration did not reduce infarct size or improve clinical outcomes in patients with STEMI.
• The findings suggest that STS is not effective in mitigating reperfusion injury in this context.
• Further research may be needed to explore STS in different patient subgroups or conditions.